Feed aggregator

Merz to create three independent, customer-focused healthcare businesses to drive growth

World Pharma News - Wed, 11/13/2019 - 13:00
Merz, a global, diversified healthcare company, has announced plans for a new business structure that will enable the company to better address customer and patient needs, shorten innovation cycles and capitalize on new market opportunities.

Mylan and Pfizer announce Viatris as the new company name in the planned Mylan-Upjohn combination

World Pharma News - Wed, 11/13/2019 - 11:00
HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced 'viǝ-trīs).

Kiadis to Restructure Months After Acquiring CytoSen Therapeutics

Biospace news - Wed, 11/13/2019 - 02:00
The company will discontinue development of its lead T-cell asset, ATIR101, halt its ongoing Phase III trial and lay off half its staff.

Merck Snaps Up Preclinical Neurodegenerative Asset in $576 Million Buy

Biospace news - Wed, 11/13/2019 - 02:00
Merck plunked down $576 million to acquire San Diego-based Calporta to gain access to preclinical TRPML1 agonists that are seen as potential treatments for neurodegenerative disorders such as Alzheimer’s or Parkinson’s.

Amgen Exits Neuroscience R&D, Plans to Cut 149 Jobs in Boston Area

Biospace news - Wed, 11/13/2019 - 02:00
Unfortunately, this makes Amgen yet another major biopharma company to exit or slim down work on neurological diseases. Others include Pfizer, Bristol-Myers Squibb, GlaxoSmithKline and AstraZeneca.

Tracking and Delivering Targeted Cancer Therapeutics with Microbubbles and Sound Waves

Biospace news - Wed, 11/13/2019 - 02:00
Biomedical engineers at the University of Southern California developed a method using ultrasound to control and track drug release.

GSK's Nucala Hits the Mark in Phase III HES Trial, Setting Up Potential Approval

Biospace news - Wed, 11/13/2019 - 02:00
HES is a rare group of inflammatory disorders that affects approximately 20,000 people around the world.

Weill Neurohub Will Promote Cross-Institutional Collaboration in Brain Trauma and Neurodegenerati...

Biospace news - Wed, 11/13/2019 - 02:00
The Weill Family Foundation, University of California, Berkeley, University of California, San Francisco and the University of Washington launched the Weill Neurohub with a $106 million gift.

What Does an Employer Really Mean When Asking "Why Should We Hire You?"

Biospace news - Wed, 11/13/2019 - 02:00
“Why should we hire you?” is a question frequently asked in job interviews, but what’s really behind the question, and how should you respond to it?

Is DNA the Data Storage of the Future?

Biospace news - Wed, 11/13/2019 - 02:00
DNA is structurally suited to storing information for extended periods of time, given its half-life of 521 years.

3 Tips for Successfully Managing Your Time Better at Work

Biospace news - Wed, 11/13/2019 - 02:00
Of the 40+ hours you spend at your desk or in your office each week, how many are actually spent being productive?

Protein could offer therapeutic target for pancreatic cancer

World Pharma News - Tue, 11/12/2019 - 13:00
A protein that drives growth of pancreatic cancer, and which could be a target for new treatments, has been identified by researchers at the Crick. The study, published in Nature Cell Biology, looked into the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma. This is an aggressive cancer that develops from secretory and tubular cells of the pancreas.

Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade

World Pharma News - Tue, 11/12/2019 - 11:00
4 - 5 February 2020, London, UK.
SMi presents Europe's leading 14th annual Parallel Trade conference, taking place in London. As the only B2B parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

FDA Slaps Second Clinical Hold on Solid Biosciences’ DMD Gene Therapy Due to Adverse Event

Biospace news - Tue, 11/12/2019 - 02:00
In its announcement, Solid Biosciences said a patient in its second cohort who was dosed in October experienced a serious adverse event that was deemed related to the drug.

Recent Financing Rounds in the Biopharma Industry

Biospace news - Tue, 11/12/2019 - 02:00
BioSpace takes a look at some of the financing rounds announced over the past few weeks.

AstraZeneca's Anifrolumab for Lupus Has Potential to Compete with GlaxoSmithKline's Benlysta

Biospace news - Tue, 11/12/2019 - 02:00
The experimental drug, if approved, will compete with GlaxoSmithKline's Benlysta, which is the only new drug approved for lupus in the last 60 years.

Overview: The Lower Drug Costs Now Act of 2019 and the American Pharmaceutical Industry

Biospace news - Tue, 11/12/2019 - 02:00
H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act (cited as the Lower Drug Costs Now Act of 2019), is a bill before the House that is intended to make prescription drugs more affordable for those in the Medicare program.

Biotech In-Demand Job: Medical and Health Service Managers

Biospace news - Tue, 11/12/2019 - 02:00
Medical and health service managers work hard to improve the quality and efficiency required to deliver first rate healthcare services.

CNS Summit: Discussions on Virtual and Hybrid Clinical Trials

Biospace news - Tue, 11/12/2019 - 02:00
Jonathan Cotliar, chief medical officer of Science 37, a leader in virtual clinical trials, took time to speak with BioSpace about virtual and hybrid clinical trials, the CNS Summit and Science 37.

Unexpected Findings in Parkinson’s Research Show Cells May Not Be Dead

Biospace news - Tue, 11/12/2019 - 02:00
Researchers found neurons may shut down without dying and these “undead neurons” release molecules that shut down neighboring brain cells, which leads to the common Parkinson’s symptoms.